These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 32614964)

  • 1. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.
    Wudhikarn K; Pennisi M; Garcia-Recio M; Flynn JR; Afuye A; Silverberg ML; Maloy MA; Devlin SM; Batlevi CL; Shah GL; Scordo M; Palomba ML; Dahi PB; Sauter CS; Santomasso BD; Mead E; Perales MA
    Blood Adv; 2020 Jul; 4(13):3024-3033. PubMed ID: 32614964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
    Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
    Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.
    Wudhikarn K; Palomba ML; Pennisi M; Garcia-Recio M; Flynn JR; Devlin SM; Afuye A; Silverberg ML; Maloy MA; Shah GL; Scordo M; Dahi PB; Sauter CS; Batlevi CL; Santomasso BD; Mead E; Seo SK; Perales MA
    Blood Cancer J; 2020 Aug; 10(8):79. PubMed ID: 32759935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.
    Penack O; Peczynski C; Koenecke C; Polge E; Sanderson R; Yakoub-Agha I; Fegueux N; Daskalakis M; Collin M; Dreger P; Kröger N; Schanz U; Bloor A; Ganser A; Besley C; Wulf GG; Novak U; Moiseev I; Schoemans H; Basak GW; Chabannon C; Sureda A; Glass B; Peric Z
    Front Immunol; 2023; 14():1252811. PubMed ID: 37828980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicities of CD19 CAR-T cell immunotherapy.
    Hirayama AV; Turtle CJ
    Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
    Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
    J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.
    Fan L; Wang L; Cao L; Zhu H; Xu W; Li J
    Front Med; 2022 Apr; 16(2):285-294. PubMed ID: 34727319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
    Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
    J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
    Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
    He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma.
    Mirza AS; Kumar A; Hashmi H; Garcia F; Logothetis CN; Darwin A; Faramand R; Reid K; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Nishihori T; Locke FL; Jain MD
    Transplant Cell Ther; 2021 Mar; 27(3):242.e1-242.e6. PubMed ID: 33781520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: a discrete choice experiment.
    Birch K; Snider JT; Chiu K; Baumgardner J; Wade SW; Shah G
    Future Oncol; 2022 Aug; 18(25):2791-2804. PubMed ID: 35837970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
    Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
    Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.